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Background. Shigella, a major diarrheal disease pathogen worldwide, is the target of vaccine development. The
Global Enteric Multicenter Study (GEMS) investigated burden and etiology of moderate-to-severe diarrheal disease
in children aged <60 months and matched controls without diarrhea during 3 years at 4 sites in Africa and 3 in Asia.
Shigella was 1 of the 4 most common pathogens across sites and age strata. GEMS Shigella serotypes are reviewed to
guide vaccine development.
Methods. Subjects’ stool specimens/rectal swabs were transported to site laboratories in transport media and
plated onto xylose lysine desoxycholate and MacConkey agar. Suspect Shigella colonies were identiﬁed by biochem-
ical tests and agglutination with antisera. Shigella isolates were shipped to the GEMS Reference Laboratory (Balti-
more, MD) for conﬁrmation and serotyping of S. ﬂexneri; one-third of isolates were sent to the Centers for Disease
Control and Prevention for quality control.
Results. Shigella dysenteriae and S. boydii accounted for 5.0% and 5.4%, respectively, of 1130 Shigella case iso-
lates; S. ﬂexneri comprised 65.9% and S. sonnei 23.7%. Five serotypes/subserotypes comprised 89.4% of S. ﬂexneri,
including S. ﬂexneri 2a, S. ﬂexneri 6, S. ﬂexneri 3a, S. ﬂexneri 2b, and S. ﬂexneri 1b.
Conclusions. A broad-spectrum Shigella vaccine must protect against S. sonnei and 15 S. ﬂexneri serotypes/sub-
serotypes. A quadrivalent vaccine with O antigens from S. sonnei, S. ﬂexneri 2a, S. ﬂexneri 3a, and S. ﬂexneri 6 can
provide broad direct coverage against these most common serotypes and indirect coverage against all but 1 (rare)
remaining subserotype through shared S. ﬂexneri group antigens.
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The Global Enteric Multicenter Study (GEMS) of the burden
and etiology of moderate-to-severe diarrheal illness (MSD) in
children aged <5 years performed over 3 years at 4 sites in
sub-Saharan Africa (Basse, The Gambia; Bamako, Mali; Siaya
County, Kenya; Manhiça, Mozambique) and 3 in South Asia
(Karachi, Pakistan; Kolkata, India; Mirzapur, Bangladesh) es-
tablished Shigella as 1 of 4 top pathogens [1]. The increased
diagnostic yield observed when stool specimens are examined
using gel-based or quantitative real-time polymerase chain reac-
tion (PCR) suggests that the burden of disease may be greater
than estimated using standard cultures [2, 3]. Although pediat-
ric morbidity from shigellosis remains substantial, mortality has
diminished, in part, because of the virtual disappearance world-
wide of the highly virulent Shiga toxin-producing S. dysenteriae
1 serotype and because World Health Organization guidelines
recommend antibiotic treatment for clinical dysentery (diarrhea
with gross blood). Regrettably, Shigella relentlessly acquires re-
sistance to antibiotics that were previously effective in diminish-
ing disease severity and duration and pathogen excretion [2, 4].
Based on clinical severity, disease burden, and emergence of
antimicrobial resistance, Shigella is a prime target for vaccine
development [2, 4–6]. The 4 species (also called groups or sub-
groups) of Shigella encompass 50 serotypes and subserotypes
that include the following: S. dysenteriae (15 serotypes); S. ﬂex-
neri (15 serotypes and subserotypes, including S. ﬂexneri 1a, 1b,
2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6, X, and Y and 2 new subserotypes
7a and 7b, previously referred to as Shigella provisional 88–893,
Y394, or “S. ﬂexneri 1c” [7]);S. boydii (19 serotypes); and S. son-
nei (1 serotype). The distinct serotypes/subserotypes are deﬁned
by conformational epitopes of their O polysaccharide antigens
[6]. Challenge/rechallenge studies in nonhuman primates [8]
and volunteers [9–11], epidemiological ﬁeld studies [12], and
seroepidemiological studies [13, 14] indicate that clinical infec-
tion with wild type Shigella strains bestows approximately 75%
subgroup-speciﬁc (and usually subserotype-speciﬁc) immunity.
Live oral vaccines [15–18] and O-polysaccharide-protein conju-
gate vaccines [19, 20] that have conferred protection in random-
ized controlled ﬁeld trials corroborate the importance of
immune responses to Shigella O antigens. Most Shigella vac-
cines in clinical development are based on eliciting protection
against multiple epidemiologically important serotypes. Ac-
cordingly, to rationally guide vaccine formulation, it is impera-
tive to have robust data on the distribution of Shigella serotypes
associated with shigellosis. GEMS serotype data provide such
information from the geographic areas where 80% of deaths
due to diarrheal disease among young children occur [1, 21].
MATERIALS AND METHODS
Conducted over 3 years, GEMS was an age-stratiﬁed, matched
case-control study of MSD among children aged 0–59 months
residing in censused populations and seeking care at medical
facilities serving 7 sites in sub-Saharan Africa and South Asia.
Rationale for the GEMS and detailed clinical, epidemiologic,
and microbiological methods have been published elsewhere
[21–24].
Epidemiological and Clinical Methods
The University of Maryland, Baltimore Institutional Review
Board and ethics committees at each ﬁeld site approved the
protocol. A censused population provided the sampling
frame at each study site where sentinel hospitals or health cen-
ters serving the population enrolled cases from 3 age strata: in-
fants (0–11 months), toddlers (12–23 months), and young
children (24–59 months) [1, 24]. Age-eligible children from
the censused population visiting the centers with diarrhea
(≥3 loose stools in the previous 24 hours) were examined
for eligibility. To be included, the child’s diarrheal episode
had to be new (onset after ≥7 diarrhea-free days), acute (du-
ration <7 days), and had to meet at least 1 of the following cri-
teria deﬁning MSD: clinical evidence of moderate-to-severe
dehydration (sunken eyes, loss of skin turgor, or initiation of
intravenous ﬂuids based on clinical judgment); dysentery; or
clinical judgment that the child with diarrheal illness needed
to be hospitalized. For each MSD case, 1–3 (occasionally 4)
controls without diarrhea, randomly selected from each site’s
census database and matched by age, gender, and residential
community, were enrolled within 14 days of the matched
index case.
Upon enrollment, each case and matched control provided a
stool specimen (≥3 grams) that, within 1 hour of passage, was
stored cold until delivered to the laboratory. If antibiotics were
to be administered to patients before stool was produced, 2 rec-
tal swabs were obtained for bacterial culture pending passage of
whole stool for the remaining assays.
Bacteriologic Methods
Stool samples/rectal swabs were introduced into Cary–Blair and
buffered glycerol saline (BGS) transport media, the latter to en-
hance yield of Shigella [22, 25]; inoculation onto solid media oc-
curred within 18 hours. To isolate Shigella, the BGS swab was
plated onto MacConkey and xylose lysine desoxycholate agar.
After incubation at 37°C, suspicious colonies were subjected
to biochemical tests [22]. Shigella isolates at the ﬁeld sites
were serotyped with polyvalent group A, B, C, and D antisera
(Denka Seiken Co., Ltd., Tokyo, Japan or Reagensia AB,
Solna, Sweden) and shipped to the GEMS Reference Laboratory
at the Center for Vaccine Development (CVD) for conﬁrmation
and identiﬁcation of individual S. ﬂexneri serotypes/subsero-
types and S. dysenteriae 1. One-third of isolates serotyped at
CVD were sent to the Centers for Disease Control and Preven-
tion (CDC) for serotype conﬁrmation.
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Chromosomal genes encoding Shigella enterotoxin 1
(ShET1) [26, 27] were ampliﬁed by PCR using the following
primers:
set1AForward: 5′- CAG CGT CTT TCA GCG ACA GTG
TTT -3′
set1AReverse: 5′- AGC ATG ATA CTC AAC AGC CAG
ACC -3′
set1BForward: 5′- ATA CTG GCT CCT GTC ATT CAC
GGT -3′
set1BReverse: 5′- GGA AGT GAC AGG GCA TTT GTG
GAT -3′ [28, 29].
Statistical Methods
Distributions of species were compared by χ2 test with 3 degrees
of freedom. Individual species and subserotypes were compared
using χ2 test with no continuity correction or 2-sided Fisher
exact test. P≤ .05 was considered statistically signiﬁcant.
RESULTS
We investigated 1130 Shigella isolates from cases (1120 from the
matched case-control dataset [1] and 10 from MSD cases for
whom there was no control) and 219 isolates from controls
without diarrhea; 11 other isolates from the sites (9 cases and
2 controls) were not sent to CVD. The distribution of Shigella
species among case isolates is shown in Table 1. Only 5.0% of
case isolates (N = 56) were S. dysenteriae (none were S. dysenter-
iae 1) and 5.4% (N = 61) were S. boydii. Overall, 89.6% of case
isolates were S. ﬂexneri (N = 745; 65.9%) or S. sonnei (N = 268;
23.7%). Four serotypes/subserotypes, S. ﬂexneri 2a, S. ﬂexneri
2b, S. ﬂexneri 3a, and S. ﬂexneri 6, comprised 581 of the 745
S. ﬂexneri isolates (78.0%; Table 1); inclusion of S. ﬂexneri 1b
raises the total to 89.4% of all S. ﬂexneri.
Mirzapur, Bangladesh, where shigellosis exhibits a striking
seasonal peak [30], contributed the most Shigella cases. Thus,
it was important to compare Bangladesh serotype data with
data from the other 6 GEMS sites (Table 1). The overall species
distributions in Bangladesh and the other sites combined were
signiﬁcantly different (P = .015), but the absolute differences for
individual species were modest. Percentages of the 2 most prev-
alent species, S. ﬂexneri and S. sonnei, were similar and not sig-
niﬁcantly different in Bangladesh vs the combined other sites.
The percentages of S. ﬂexneri subserotypes were signiﬁcantly
different only for S. ﬂexneri 1b, S. ﬂexneri 2b, S. ﬂexneri 6,
and S. ﬂexneri X. The proportion of isolates that were S. ﬂexneri
plus S. sonnei by year of the study at all sites, Bangladesh, and
the 6 sites other than Bangladesh is shown in Table 2. Remark-
ably, there was little variation.
Among 219 isolates from control subjects (Table 1), there was
less representation of S. ﬂexneri (N = 115; 52.5%) compared with
cases, where 65.9% of all isolates were S. ﬂexneri (P < .001). Shi-
gella ﬂexneri 2a, S. ﬂexneri 2b, S. ﬂexneri 3a, and S. ﬂexneri 6 ac-
counted for 78.0% of S. ﬂexneri case isolates vs 71.3% of control
S. ﬂexneri isolates. Shigella ﬂexneri 2a ranked ﬁrst in frequency
followed by S. ﬂexneri 6 among cases; among controls, S. ﬂexneri
6 ranked ﬁrst followed by S. ﬂexneri 2a.
There was excellent concordance between CVD and CDC re-
sults in serotyping quality control. The 46 S. dysenteriae isolates
sent by CVD were conﬁrmed by CDC as S. dysenteriae sero-
types 2 (N = 17), 3 (N = 10), 4 (N = 12), 8 (N = 1), 9 (N = 1),
and 12 (N = 5). CDC conﬁrmed 76 of 77 putative S. boydii
that they serotyped as S. boydii 1 (N = 11), 2 (N = 16),
3 (N = 1), 4 (N = 16), 5 (N = 1), 7 (N = 1), 8 (N = 4), 10 (N = 9),
11 (N = 1), 12 (N = 4), 14 (N = 3), 15 (N = 2), 18 (N = 3), and 20
(N = 5); the remaining isolate was Escherichia albertii, which is
known to share O antigens with S. boydii 13 [31]. Of 37 putative
S. sonnei isolates, 36 were conﬁrmed and 1 was found by CDC
to be S. dysenteriae-like provisional serotype 96–3162 serotype.
CDC conﬁrmed CVD’s subserotyping of 146 of the 147
S. ﬂexneri sent, the exception being a strain identiﬁed by
CVD as S. ﬂexneri 1b but shown by CDC to be S. dysenteriae
3 (strain mix-up). Finally, 22 Shigella isolates sent by CVD
were deemed untypable with available reagents. CDC identiﬁed
21 of the 22; 20 were S. dysenteriae-like provisional serotype 96–
3162 and 1 was S. boydii-like provisional serotype 2009C-3081.
ShET1, a classic enterotoxin consisting of 1 enzymatically ac-
tive A subunit linked to 5 binding B subunits, is encoded by
setAB [26, 32] located within chromosomal Shigella pathogenic-
ity island 1 [26, 32], originally identiﬁed in S. ﬂexneri 2a. Nota-
bly, 85 of 86 GEMS S. ﬂexneri 2a tested positive for ShET1, as
did all 33 S. ﬂexneri 2b strains tested. Only 4 of 134 (3.0%) iso-
lates of other S. ﬂexneri serotypes were positive, including 2/2
S. ﬂexneri 5b, 1/1 S. ﬂexneri Y, and 1/22 S. ﬂexneri 3a.
DISCUSSION
Natural immunity to Shigella is largely based on immune re-
sponses to O antigens. Follow-up of a Chilean pediatric cohort
where S. sonnei, S. ﬂexneri 2a, and S. ﬂexneri 6 were the most
prevalent serotypes (79% of cases) indicated that an initial epi-
sode of shigellosis conferred approximately 75% protection
against subsequent shigellosis due to the same serotype but
did not signiﬁcantly cross protect against illness caused by the
other predominant serotypes [12]. Seroepidemiological studies
from Israel corroborate the importance of preexistent O anti-
body (denoting prior exposure) in lowering the risk of S. sonnei
and S. ﬂexneri 2a disease [13, 14]. Accordingly, developers of
vaccines to prevent shigellosis have designed serotype-based
vaccines [4, 6], some of which have conferred signiﬁcant protec-
tion [9, 15–20, 33].
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Table 1. Species and Serotype Distribution by Site of 1130 Shigella Isolates From Children Aged <60 Months With Moderate to Severe Diarrhea in the Global Enteric Multicenter Study
and of 219 Isolates From Control Children Without Diarrhea
Cases Controls
Serogroup, Serotype,
or Subserotype
All 7 GEMS
Sites
6 GEMS Sites
Other
Than Bangladesh Bangladesh Pakistan India Gambia Mali Kenya Mozambique
All 7 GEMS
Sites
Total isolates 1130 519 611 129 91 116 41 105 37 219
Shigella dysenteriae 56 (5.0%)a 33 (6.4%)b 23 (3.8%)c 6 (4.7%)c 2 (2.2%)c 5 (4.3%)c 1 (2.4%)c 19 (18.1%)c 0 10 (4.6%)
S. boydii 61 (5.4%)a 37 (7.1%)b 24 (3.9%) 10 (7.8%) 10 (11.0%) 7 (6.0%) 2 (4.9%) 6 (5.7%) 2 (5.4%)c 24 (11.0%)
S. sonnei d 268 (23.7%)a 119 (22.9%)b 149 (24.4%) 29 (22.5%) 32 (35.2%) 24 (20.7%) 12 (29.3%) 17 (16.2%) 5 (13.5%) 70 (32.0%)
S. flexneri 745 (65.9%)a 330 (63.6%)b 415 (67.9%) 84 (65.1%) 47 (51.7%) 80 (69.0%) 26 (63.4%) 63 (60.0%) 30 (81.1%) 115 (52.5%)
S. flexneri d serotypes/subserotypes
1a 3 (0.3%)a 1 (0.2%)b 2 (0.3%)c 1 (0.8%)c 0 0 0 0 0 0
1b 85 (7.5%)a 55 (10.6%) 30 (4.9%) 12 (9.3%) 1 (1.1%)c 15 (12.9%)c 8 (19.5%)c 15 (14.3%)c 4 (10.8%)c 19 (8.7%)
2a 228 (20.2%)a 101 (19.5%) 127 (20.8%) 21 (16.3%) 24 (26.4%) 35 (30.2%) 5 (12.2%) 2 (1.9%) 14 (37.8%) 21 (9.6%)
2b 123 (10.9%)a 12 (2.3%) 111 (18.2%) 0 0 4 (3.5%) 4 (9.8%) 4 (3.8%) 0 9 (4.1%)
3a 106 (9.4%)a 47 (9.0%) 59 (9.7%) 12 (9.3%) 11 (12.1%) 5 (4.3%) 2 (4.9%) 14 (13.3%) 3 (8.1%) 17 (7.8%)
3b 1 (0.1%)a 0 1 (0.2%) 0 0 0 0 0 0 0
4a 33 (2.9%)a 19 (3.7%) 14 (2.3%) 9 (7.0%) 4 (4.4%) 0 1 (2.4%) 5 (4.8%) 0 6 (2.7%)
4b 0 0 0 0 0 0 0 0 0 0
5a 0 0 0 0 0 0 0 0 0 0
5b 3 (0.3%)a 0 3 (0.5%) 0 0 0 0 0 0 1 (0.5%)
6 124 (11.0%)a 70 (13.5%) 54 (8.9%) 23 (17.8%) 5 (5.5%) 12 (10.3%) 4 (9.8%) 19 (18.1%) 7 (18.9%) 35 (16.0%)
7ae 23 (2.0%)a 13 (2.5%) 10 (1.6%) 6 (4.7%) 2 (2.2%) 1 (0.9%) 0 4 (3.8%) 0 6 (2.7%)
7be 0 0 0 0 0 0 0 0 0 0
X 11 (1.0%)a 11 (2.1%) 0 0 0 7 (6.0%) 2 (4.9%) 0 2 (5.4%) 1 (0.5%)
Y 5 (0.4%)a 1 (0.2%) 4 (0.7%) 0 0 1 (0.9%) 0 0 0 0
The distribution of species among the Bangladesh isolates was significantly different (P = .015) from the composite of the other 6 GEMS sites. The percentage of the various S. flexneri serotypes and subserotypes
isolated in Bangladesh was significantly different from the percentage at the other 6 sites for the greater percentage of S. flexneri 2b in Bangladesh (P < .0001) and the lower percentages of S. flexneri 1b (P = .0003),
S. flexneri 6 (P = .015), and S. flexneri X (P = .0002).
Abbreviation: GEMS, Global Enteric Multicenter Study.
a Percent of all 1130 case isolates from the composite of all 7 sites.
b Percent of the total 519 case isolates from the 6 GEMS sites other than Bangladesh.
c Percent of the total isolates from the individual GEMS site.
d Bolded S. flexneri serotypes/subserotypes are those proposed for inclusion, along with S. sonnei, in a quadrivalent broad-spectrum Shigella vaccine.
e S. flexneri 7 strains were previously referred to as Shigella “provisional 88–893,” “provisional Y394,” or “S. flexneri 1c.”
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Table 2. Prevalence of Shigella sonnei and S. ﬂexneri Serogroups and Proposed Vaccine Component Serotypes of S. ﬂexneri Among Shigella Isolates From Global Enteric
Multicenter Study Cases by Year of the Study
All 7 GEMS Sites 6 GEMS Sites Other Than Bangladesh Bangladesh
Serogroup, Serotype,
or Subserotype Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Total isolates 457 345 328 214 142 163 243 203 165
S. sonnei 94 (20.6%)a 76 (22.0%)a 98 (29.9%)a 53 (24.8%)b 27 (19.0%)b 39 (23.9%)b 41 (16.9%)c 49 (24.1%)c 59 (35.8%)c
S. flexneri 317 (69.4%)a 231 (67.0%)a 197 (60.1%)a 134 (62.6%)b 94 (66.2%)b 102 (62.6%)b 183 (75.3%)c 137 (67.5%)c 95 (57.6%)c
S. flexneri + S. sonnei 411 (89.9%)a 307 (89.0%)a 295 (89.9%)a 187 (87.4%)b 121 (85.2)b 141 (86.5%)b 224 (92.2%)c 186 (91.6%)c 154 (93.3%)c
S. flexneri 2a, 3a and 6 183 144 131 97 54 67 86 90 64
As % of all S. flexneri 57.7%d 62.3% 66.5% 72.4%e 57.5% 65.7% 47.0%f 65.7% 67.4%
As % of all isolates 40.0%a 41.7% 39.9% 45.3%b 38.0% 41.1% 35.4%c 44.3% 38.8%
S. sonnei+ S. flexneri 2a, 3a and 6 277 (60.6%)a 220 (63.8%) 229 (69.8%) 150 (70.1%)b 81 (57.0%) 106 (65.0%) 127 (52.3%)c 139 (68.5%) 123 (74.6%)
S. sonnei+ all S. flexneri serotypes other
than S. flexneri 7a
403 (88.2%)a 296 (85.8%) 291 (88.7%) 182 (85.1%)b 116 (81.7%) 138 (84.7%) 221 (91.0%)c 180 (88.7%) 153 (92.7%)
Abbreviation: GEMS, Global Enteric Multicenter Study.
a Percent of all case isolates for particular study year for all 7 GEMS sites.
b Percent of all case isolates for particular study year for 6 GEMS sites other than Bangladesh.
c Percent of all case isolates for particular study year for Bangladesh.
d Percent of all S. flexneri isolates for particular study year for all 7 GEMS sites.
e Percent of all S. flexneri isolates for particular study year for 6 GEMS sites other than Bangladesh.
f Percent of all S. flexneri isolates for particular study year for Bangladesh.
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One obstacle to developing serotype-based Shigella vaccines
is choosing the minimal number from among 50 serotypes.
The more serotypes included, the more complex and expensive
the vaccine, leading some investigators to pursue common pro-
tein vaccines [34]. However, the extensive GEMS serotype data
frommultiple locations over several years constitutes a hallmark
resource to guide vaccine development and provides optimism
for serotype-based vaccines.
During GEMS, the fearsome S. dysenteriae 1 serotype, which
caused protracted pandemics of severe disease from the 1960s to
the1990s in Central America [35],Asia [36], and Africa [37, 38],
was not isolated nor were there S. dysenteriae 1 outbreaks re-
ported during 2006–2013. This suggests one may exclude S. dys-
enteriae 1 from a multivalent vaccine to prevent endemic
shigellosis in developing countries. Nevertheless, should public
health authorities deem it critical that a S. dysenteriae 1 vaccine
be available for future resurgences of pandemic Shiga dysentery,
a monovalent vaccine could be stockpiled [39]. Since absence of
Shiga disease precludes a controlled ﬁeld trial, prelicensure efﬁ-
cacy must be demonstrated in alternative ways (eg, volunteer
challenges with a nontoxigenic strain) [40].
Although S. dysenteriae has 15 and S. boydii has 19 distinct
serotypes, they accounted for only 5.0% and 5.4%, respectively,
of all Shigella case isolates. Assuming distributions do not chan-
ge dramatically over longer time periods, excluding these sero-
types from a vaccine would have little impact on breadth of
coverage. In contrast, S. ﬂexneri serotypes/subserotypes com-
prised 65.9% of all Shigella case isolates, making it imperative
that coverage be provided against the most important S. ﬂexneri
subserotypes. Interestingly, a mere 5 of the 15 currently recog-
nized S. ﬂexneri serotypes/subserotypes accounted for 89.4% of
S. ﬂexneri isolates, including (in rank order) S. ﬂexneri 2a,
S. ﬂexneri 6, S. ﬂexneri 2b, S. ﬂexneri 3a, and S. ﬂexneri 1b. Nev-
ertheless, the relative distribution of S. ﬂexneri subserotypes
may change over time in various geographic locales. Thus, it
will be prudent for Shigella vaccines to provide coverage against
all 15 S. ﬂexneri serotypes/subserotypes.
CVD investigators devised a strategy to achieve broad-
spectrum coverage against all S. ﬂexneri serotypes except un-
common S. ﬂexneri 7a by presenting to the immune system a
mix of the following 3 serotypes: S. ﬂexneri 2a, S. ﬂexneri 3a,
and S. ﬂexneri 6 [6, 41]. Shigella ﬂexneri 6 is common, and its
O antigen is distinct from other S. ﬂexneri. Indeed, genomic
evidence indicates S. ﬂexneri 6 might more appropriately be
classiﬁed as a S. boydii serotype; however, for historical and
practical reasons, it retains designation as a S. ﬂexneri serotype.
Shigella ﬂexneri serotypes/subserotypes other than S. ﬂexneri
6 have O antigens that share a common backbone structure that
consists of tetrasaccharide repeats of 3 rhamnose residues linked
to 1 N-acetylglucosamine [6]. Genes encoding the enzymes that
synthesize the tetrasaccharide backbone reside in the S. ﬂexneri Ta
bl
e
3.
Tw
el
ve
Se
ro
ty
pe
s
an
d
Su
bs
er
ot
yp
es
of
Sh
ig
el
la
ﬂ
ex
ne
ri
N
ot
in
th
e
Qu
ad
riv
al
en
tV
ac
ci
ne
an
d
O
Gr
ou
p
An
tig
en
s
Th
at
Th
ey
Sh
ar
e
W
ith
th
e
Va
cc
in
e
Se
ro
ty
pe
s
S
er
ot
yp
es
in
th
e
Q
ua
dr
iv
al
en
t
Sh
ig
el
la
Va
cc
in
e
(a
nd
th
ei
r
O
an
tig
en
s)
12
S
er
ot
yp
es
an
d
S
ub
se
ro
ty
pe
s
of
S.
fle
xn
er
iN
ot
in
th
e
Q
ua
dr
iv
al
en
t
Va
cc
in
e
1a
1b
2b
3b
4a
4b
5a
5b
7a
7b
X
Y
S.
fle
xn
er
i2
a
(ty
pe
an
tig
en
II
an
d
gr
ou
p
an
tig
en
“
3,
4”
)
G
ro
up an
tig
en
“
3,
4”
a
Ty
pe an
tig
en
IIa
G
ro
up an
tig
en
“
3,
4”
a
G
ro
up an
tig
en
“
3,
4”
a
G
ro
up an
tig
en
“
3,
4”
a
.
.
.
G
ro
up an
tig
en
“
3,
4”
a
S.
fle
xn
er
i3
a
(ty
pe
an
tig
en
III
an
d
gr
ou
p
an
tig
en
s
“
6”
an
d
“
7,
8”
)
G
ro
up an
tig
en
“
6”
a
G
ro
up an
tig
en
“
7,
8”
a
Ty
pe an
tig
en
III
a
G
ro
up an
tig
en
“
6”
a
G
ro
up an
tig
en
“
7,
8”
a
.
.
.
G
ro
up an
tig
en
“
6”
a
G
ro
up an
tig
en
“
7,
8”
a
S.
fle
xn
er
i6
(ty
pe
an
tig
en
V
I)
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
a
S.
fle
xn
er
it
yp
e
an
d
gr
ou
p
an
tig
en
s
th
at
ar
e
sh
ar
ed
w
ith
th
e
S.
fle
xn
er
is
er
ot
yp
es
/s
ub
se
ro
ty
pe
s
th
at
ar
e
in
th
e
va
cc
in
e
an
d
th
at
co
ns
tit
ut
e
th
e
im
m
un
ol
og
ic
ba
si
s
fo
r
cr
os
s
pr
ot
ec
tio
n.
938 • CID 2014:59 (1 October) • Livio et al
chromosomal rfb locus. Shigella ﬂexneri Y’s O antigen consists
of tetrasaccharide repeats without further modiﬁcations. How-
ever, lysogenic bacteriophages that encode enzymes able to dec-
orate the tetrasaccharide backbone at speciﬁc sites with O-acetyl
or D-glucose moieties create new epitopes or ablate others and
result in modiﬁed saccharide structures that represent the other
S. ﬂexneri serotypes [6]. The epitopes created by these O-acetyl
and D-glucose groups also constitute group antigens shared
among different S. ﬂexneri serotypes. If the shared group
and type-speciﬁc antigens induce cross-protective immunity,
the number of subserotypes required for a broadly effective
Shigella vaccine can be minimized. Thus, a multivalent vaccine
that includes S. ﬂexneri 2a and S. ﬂexneri 3a (Table 3), in ad-
dition to cross protecting against S. ﬂexneri 2b (via type 2 an-
tigen) and S. ﬂexneri 3b (via type 3 antigen), would provide
shared group antigens that could elicit cross protection against
S. ﬂexneri 1a, 3b, 4a, 5a, and Y (via group antigen 3,4);
against S. ﬂexneri 1b, 3b, 4b, and 7b (via group antigen 6);
and against S. ﬂexneri 2b, 5b, and X (via group 7,8). No
cross protection could accrue against S. ﬂexneri 6, as its O tet-
rasaccharide structure (rhamnose-rhamnose-D-galactose-N-
acetylgalactosamine) is distinct and lacks the group antigens
shared by other S. ﬂexneri serotypes.
Noriega et al [41] used the guinea pig Sereny keratoconjunc-
tivitis model to measure cross-reacting serological responses
and cross protection when animals immunized mucosally
with a live bivalent vaccine containing S. ﬂexneri 2a and S. ﬂex-
neri 3a were challenged with other S. ﬂexneri subserotypes. Sig-
niﬁcant cross protection was demonstrated against challenge
with heterologous serotypes/subserotypes including S. ﬂexneri
Y, 1b, 2b, and 5b; protection against S. ﬂexneri 1a was borderline
(P = .065). As expected, no cross protection was observed in im-
munized animals challenged with S. ﬂexneri 6 [41].
Following S. ﬂexneri 2a illness or vaccination with live oral
vaccine expressing S. ﬂexneri 2a O antigen, the human immune
system mounts cross-reacting antibody responses against other
S. ﬂexneri serotypes that share type or group antigens [42]. If the
cross protection observed in animals can be extrapolated to hu-
mans, a multivalent vaccine that includes O antigens of S. son-
nei, S. ﬂexneri 2a, S. ﬂexneri 3a, and S. ﬂexneri 6 would provide
direct coverage against approximately 64% of the GEMS Shigel-
la strains, and cross protection could provide up to 88% overall
coverage. Indeed, only S. ﬂexneri 7a (merely 2.0% of GEMS iso-
lates) lacks any of the mentioned shared group antigens; S. ﬂex-
neri 7b expresses group antigen 6. Excluding S. ﬂexneri 7a from
a multivalent vaccine would have little impact on global breadth
of coverage.
Table 2 displays GEMS serotypes in relation to the proposed
quadrivalent vaccine composition (S. ﬂexneri 2a, S. ﬂexneri 3a,
S. ﬂexneri 6 plus S. sonnei) to estimate breadth of coverage and
possible variation over time from the perspective of all 7 GEMS
sites, the site with the most Shigella cases (Bangladesh), and the
other 6 sites. Only minimal changes in serotypes are seen from
year to year; matching of serotypes between circulating strains
and vaccine composition would provide 52%–75% direct pro-
tection and, with shared group antigens, 82%–93% coverage
can be achieved via cross protection.
One other multicenter study used systematic surveillance
to detect Shigella cases, quantify the burden of shigellosis,
and identify serotypes [2]. Von Seidlein et al [2] used a differ-
ent deﬁnition of diarrheal illness as the eligibility criterion for
enrollment, obtained strains from older subjects as well as
children aged <5 years, maintained surveillance for different
time periods (1–3 years, depending on the site), and worked
only in Asia (China, Thailand, Vietnam, Indonesia, Bangla-
desh, and Pakistan) but used microbiological methods similar
to GEMS and similarly included sites in Pakistan and Bangla-
desh. Among the total 2927 Shigella isolates reported by Von
Seidlein et al [2], 90% were either S. ﬂexneri (68%) or S. sonnei
(22%), similar to GEMS; 51% of their S. ﬂexneri isolates were
S. ﬂexneri 2a, S. ﬂexneri 3a, or S. ﬂexneri 6. Importantly, like
GEMS, they found no S. dysenteriae 1 among their 110 S. dys-
enteriae isolates [2].Via direct or via shared group antigens, the
quadrivalent vaccinewould cover at least 84.7% of the 2819 fully
serotyped Shigella strains isolated by Von Seidlein et al [2].
Preclinical and clinical evidence indicates that ShET1 con-
tributes to the watery diarrhea observed early in S. ﬂexneri 2a
clinical illness and to diarrheal adverse reactions associated
with certain live oral vaccines [26, 27, 43]; deleting set and sen
diminishes vaccine reactogenicity [43, 44]. We conﬁrmed that
ShET1 genes are common in S. ﬂexneri 2a and 2b isolates
(117/119, 98.3%) but rare among other S. ﬂexneri subserotypes
(4/137, 2.9%) or other species (2/132, 1.5%).
Serotyping of the GEMS Shigella isolates offers optimism that
a quadrivalent vaccine containing S. sonnei and 3 serotype/sub-
serotypes of S. ﬂexneri (S. ﬂexneri 2a, S. ﬂexneri 3a, and S. ﬂex-
neri 6) can provide broad coverage against Shigella, which
causes the majority of endemic pediatric shigellosis in the devel-
oping world, and also can provide broad coverage for travelers
[45, 46].
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